📰 Psychedelics News
Curated updates on microdosing, research, policy, and community.
Filters
Did New Jersey Really Just Legalize Psilocybin?
What S2283 Actually Does — and Why It Is a Research Pilot, Not Legalization In January 2026, the New Jersey Legislature passed Senate Bill S2283, formally titled the Psilocybin Behavioral Health Access and Services Ac...
Magic Yeast Is Another Way to Produce Psilocybin
Of course, Dr. K Mandrake and Virginia Haze have the tea. [...] Read More... The post Magic Yeast Is Another Way to Produce Psilocybin appeared first on DoubleBlind Mag.
Cannabis & Capitalism: Is Justice Possible in Legalization?
Join us for a critical examination of cannabis legalization's trajectory in the United States and abroad, from grassroots movement to corporatized industry.
Psychedelic Funding, Public Markets, and M&A in 2025
We have tracked every investment for the past ten years. Each year, we provide a review of the previous year’s psychedelics fundraising activity, public markets, and M&A. Here, we explore Q4 and full year 2025 via...
Discovering the Authentic Self Through Psychedelics
Oli Genn-Bash reflects on the Western pursuit of an “authentic self,” using personal psychedelic experiences to question whether self-discovery is less about uncovering a fixed identity and more about cultivating a he...
Press Release – Chacruna Launches 2026 Course on Diversity, Culture, and Social Justice in Psychedelics
The Chacruna Institute announces its nine-week live online course, Diversity, Culture, and Social Justice in Psychedelics (January–April 2026). The program explores intersectionality, equity, decolonial perspectives, ...
What to Watch Out For in the Psychedelic Sector in 2026
Ismail Lourido Ali, JD, Co-Executive Director of The Multidisciplinary Association for Psychedelic Studies (MAPS), offers thoughts on what to watch out for in the psychedelic sector in 2026. The post What to Watch Ou...
Op-Ed: Beyond Clinical Trials: Psychedelic-Assisted Therapy in Europe’s Real World
Helena Aicher, a researcher and psychotherapist working within Switzerland’s framework for limited medical use, reflects on how Europe’s psychedelics landscape evolved in 2025.
Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative
An industry wide look at how neuroplastogens are reshaping psychedelic medicine in 2026, with insights on Delix, AbbVie’s Gilgamesh acquisition, Enveric, and the shift toward nonhallucinogenic brain therapeutics. The ...
The Complexity of Developing Pharmaceutical Mescaline Drugs
PLUS, best games to play while high, DEA's new telehealth ketamine rules, and the Shipibo stewardship of ayahuasca. [...] Read More... The post The Complexity of Developing Pharmaceutical Mescaline Drugs appeared firs...
The Psychedelic News Feed: January 12 – 18, 2026
Your one-stop digest for the latest coverage of psychedelics business, policy, research and beyond, for the week commencing January 12, 2025.
What Psychedelics Actually Destabilize
This Week’s Sunday Insider: What Psychedelics quietly tear down after the trip ends.
Dionysian Cults and Free Parties
Free parties can be understood as modern expressions of ancient ritual practices – akin to the Dionysian Mysteries – where music, dance, and psychoactive substances induce ecstatic states of consciousness. The post Di...
Do Magic Mushroom Strains Actually Matter?
It’s tempting to believe that choosing the right magic mushroom strain lets you design your “ideal trip.” But biology refuses to cooperate. Here’s the reality behind mushroom strains.
Australia’s Psychedelic Experiment: Progress, Pitfalls, and What Comes Next
Here, Monica Schweickle, founder of The Psychedelic Consultancy, an Australian firm that supports professionals navigating the country’s psychedelics system, and Psychedelic Alpha Editor Josh Hardman review the progre...